Randomized comparison of 9-month stent strut coverage of
biolimus and everolimus drug-eluting stents assessed by optical
coherence tomography in patients with ST-segment elevation
myocardial infarction. Long-term (5-years) clinical follow-up
(ROBUST trial)

J 2023

Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK et. al.

Basic information

Original name

Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

Authors

JAKL, Martin (203 Czech Republic), Pavel CERVINKA (203 Czech Republic, guarantor), Jan KAŇOVSKÝ (203 Czech Republic, belonging to the institution), Petr KALA (203 Czech Republic), Martin POLOCZEK (203 Czech Republic), Michaela CERVINKOVA (203 Czech Republic), Hiram G BEZERRA, Zdenek VALENTA (203 Czech Republic) and Marco Aurelio COSTA

Edition

CARDIOLOGY JOURNAL, GDANSK, VIA MEDICA, 2023, 1897-5593

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Poland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.900 in 2022

RIV identification code

RIV/00216224:14110/23:00133406

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.5603/CJ.a2023.0013

UT WoS

001116942600001

Keywords in English

drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials

Abstract

V originále

Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)

Citovat

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK, Michaela CERVINKOVA, Hiram G BEZERRA, Zdenek VALENTA and Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). CARDIOLOGY JOURNAL. GDANSK: VIA MEDICA, 2023, vol. 30, No 6, p. 921-928. ISSN 1897-5593. Available from: https://dx.doi.org/10.5603/CJ.a2023.0013.

@article{2368963,
   author = {Jakl, Martin and Cervinka, Pavel and Kaňovský, Jan and Kala, Petr and Poloczek, Martin and Cervinkova, Michaela and Bezerra, Hiram G and Valenta, Zdenek and Costa, Marco Aurelio},
   article_location = {GDANSK},
   article_number = {6},
   doi = {http://dx.doi.org/10.5603/CJ.a2023.0013},
   keywords = {drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials},
   language = {eng},
   issn = {1897-5593},
   journal = {CARDIOLOGY JOURNAL},
   title = {Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)},
   url = {https://journals.viamedica.pl/cardiology_journal/article/view/90905},
   volume = {30},
   year = {2023}
}

TY  - JOUR
ID  - 2368963
AU  - Jakl, Martin - Cervinka, Pavel - Kaňovský, Jan - Kala, Petr - Poloczek, Martin - Cervinkova, Michaela - Bezerra, Hiram G - Valenta, Zdenek - Costa, Marco Aurelio
PY  - 2023
TI  - Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)
JF  - CARDIOLOGY JOURNAL
VL  - 30
IS  - 6
SP  - 921-928
EP  - 921-928
PB  - VIA MEDICA
SN  - 18975593
KW  - drug-eluting stent
KW  - primary percutaneous coronary intervention
KW  - stent strut coverage
KW  - optical coherence tomography
KW  - ST-segment elevation myocardial infarction
KW  - clinical trials
UR  - https://journals.viamedica.pl/cardiology_journal/article/view/90905
N2  - Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)
ER  -

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK, Michaela CERVINKOVA, Hiram G BEZERRA, Zdenek VALENTA and Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). \textit{CARDIOLOGY JOURNAL}. GDANSK: VIA MEDICA, 2023, vol.~30, No~6, p.~921-928. ISSN~1897-5593. Available from: https://dx.doi.org/10.5603/CJ.a2023.0013.

Detailed Information on Publication Record